June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Tear osmolarity measurements in ocular graft-versus-host disease patients undergoing intense pulsed light (IPL) and meibomian gland expression (MGX)
Author Affiliations & Notes
  • Srav Vegunta
    University of Arizona College of Medicine-Phoenix, Phoenix, AZ
  • Qing Wu
    Division of Health Science Research, Mayo Clinic, Scottsdale, AZ
  • Joanne F Shen
    Department of Ophthalmology, Mayo Clinic, Scottsdale, AZ
  • Footnotes
    Commercial Relationships Srav Vegunta, None; Qing Wu, None; Joanne Shen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 358. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Srav Vegunta, Qing Wu, Joanne F Shen; Tear osmolarity measurements in ocular graft-versus-host disease patients undergoing intense pulsed light (IPL) and meibomian gland expression (MGX). Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):358.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the correlation of tear osmolarity with other dry eye parameters in repeated testing in a small cohort of cGVHD subjects with ocular rosacea and severe dry eye disease (DED).

Methods: Sixteen eyes in 8 subjects with cGVHD, ocular rosacea, and severe DED after allogeneic hematologic stem cell transplantation were evaluated at 9 time points over a 12-month period during a prospective trial of efficacy of IPL and MGX. Among other variables, OSDI, meibomian glands evaluation (MGE), tear break up time (TBUT), and tear osmolarity for each eye were recorded. SAS software was used to perform Pearson correlation coefficients and paired t-test statistical analysis.

Results: 62.5% of subjects were female. Average age was 50 (range 36-64) years. The mean baseline OSDI score was 51.7 (scale 0-100). The mean baseline tear osmolarity was 316 (range 287-365). 73% of eyes had abnormal baseline tear osmolarity (≥308 mOsm/L). Tear osmolarity did not significantly correlate with OSDI, Schirmer’s, TBUT, or MGE. Unexpectedly, the right eyes’ tear osmolarity values weakly positively correlated with Schirmer’s testing (r=0.24, p=0.065). Though the OSDI scores improved 35% with IPL/MGX treatment by 5 months and sustained to 12 months (p<0.001, paired t-test), no improvement in tear osmolarity was found at 5 and 12 months.

Conclusions: There is considerable controversy about the utility of tear osmolarity in the treatment of DED. Previous researchers have recommended selecting only the worse eye tear osmolarity value as the study eye. Unlike other milder forms of DED, our clinical experience has shown asymmetric disease severity in cGVHD patients, so each eye was evaluated independently at each time interval and recorded. We did not find expected correlation between tear osmolarity and OSDI score. There was no significant correlation between tear osmolarity and other diagnostic tests. Tear osmolarity, OSDI, Schirmer’s, TBUT, and MGE were not interchangeable in the evaluation of DED in our study population. The clinical utility of monitoring severe DED in cGVHD with tear osmolarity was not apparent with the results of this limited study.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.